

## Supplemental file

**Table S1. Longitudinal psychopathological characteristics of 50 outpatients with chronic hepatitis C according to IFN treatment<sup>1</sup>: depressive and anxiety symptoms, fatigue and impulsiveness in three consecutive psychiatric interviews<sup>2</sup>.**

<i>Characteristics</i>	<i>Group</i>	<i>T0</i>	<i>T1</i>	<i>T2</i>	<i>p</i>
<b>Depressive symptoms (BDI)</b>	<i>All patients (n=50)</i>	12.5 [10.0] ± 11.1	14.6 [10.5] ± 12.0	11.6 [9.0] ± 10.9	<i>Paired T</i> T0-T1=0.162 T1-T2=0.044 T0-T2=0.415
	<i>No IFN (n=36)</i>	13.9 [10.5] ± 12.3	12.2 [7.0] ± 11.8	12.8 [11.0] ± 11.8	<i>Paired T</i> T0-T1=0.237 T1-T2=0.610 T0-T2=0.329
	<i>IFN (n=14)</i>	8.9 [9.0] ± 6.1	20.6 [18.5] ± 10.5	8.4 [6.5] ± 7.9	<i>Wilcoxon</i> T0-T1=0.001 T1-T2=0.002 T0-T2=0.572
<b>Depressive symptoms (HAD-D)</b>	<i>All patients (n=50)</i>	6.0 [5.0] ± 4.5	6.7 [6.0] ± 5.2	6.0 [5.0] ± 4.5	<i>Wilcoxon</i> T0-T1=0.210 T1-T2=0.171 T0-T2=0.991
	<i>No IFN (n=36)</i>	6.5 [5.5] ± 5.0	5.9 [4.5] ± 5.1	6.3 [5.0] ± 5.0	<i>Wilcoxon</i> T0-T1=0.843 T1-T2=0.483 T0-T2=0.735
	<i>IFN (n=14)</i>	4.6 [5.0] ± 2.4	8.8 [9.5] ± 5.3	5.4 [5.0] ± 3.1	<i>Wilcoxon</i> T0-T1=0.033 T1-T2=0.004 T0-T2=0.648
<b>Depressive symptoms (HAM-D)</b>	<i>All patients (n=50)</i>	6.5 [4.0] ± 5.8	8.5 [7.0] ± 6.8	6.6 [4.0] ± 6.4	<i>Wilcoxon</i> T0-T1=0.070 T1-T2=0.031 T0-T2=0.944
	<i>No IFN (n=36)</i>	7.3 [4.5] ± 6.3	6.4 [5.0] ± 5.2	6.9 [5.0] ± 6.3	<i>Wilcoxon</i> T0-T1=0.712 T1-T2=0.663 T0-T2=0.898
	<i>IFN (n=14)</i>	4.4 [4.0] ± 3.8	13.8 [14.0] ± 7.5	5.9 [3.5] ± 6.8	<i>Wilcoxon</i> T0-T1=0.003 T1-T2=0.001

					<i>T0-T2=0.806</i>
<b>Anxiety symptoms (HAD-A)</b>	<i>All patients (n=50)</i>	6.9 [6.0] ± 4.5	7.2 [6.0] ± 4.8	6.2 [6.0] ± 4.2	<i>Wilcoxon</i> <i>T0-T1=0.775</i> <i>T1-T2=0.049</i> <i>T0-T2=0.042</i>
	<i>No IFN (n=36)</i>	7.5 [6.5] ± 4.9	6.9 [5.5] ± 5.2	6.7 [7.0] ± 4.4	<i>Wilcoxon</i> <i>T0-T1=0.390</i> <i>T1-T2=0.713</i> <i>T0-T2=0.084</i>
	<i>IFN (n=14)</i>	5.4 [5.0] ± 2.7	8.1 [8.0] ± 3.9	4.9 [5.0] ± 3.6	<i>Wilcoxon</i> <i>T0-T1=0.107</i> <i>T1-T2=0.005</i> <i>T0-T2=0.469</i>
<b>Anxiety symptoms (HAM-A)</b>	<i>All patients (n=50)</i>	8.5 [6.0] ± 7.0	8.9 [7.0] ± 6.4	8.0 [6.0] ± 7.1	<i>Wilcoxon</i> <i>T0-T1=0.718</i> <i>T1-T2=0.165</i> <i>T0-T2=0.321</i>
	<i>No IFN (n=36)</i>	9.5 [6.0] ± 7.7	7.5 [5.5] ± 5.6	8.1 [7.0] ± 6.9	<i>Wilcoxon</i> <i>T0-T1=0.087</i> <i>T1-T2=0.571</i> <i>T0-T2=0.210</i>
	<i>IFN (n=14)</i>	6.1 [4.5] ± 4.1	12.6 [12.5] ± 7.1	7.9 [4.5] ± 7.7	<i>Wilcoxon</i> <i>T0-T1=0.009</i> <i>T1-T2=0.004</i> <i>T0-T2=0.925</i>
<b>Fatigue (BFI score)</b>	<i>All patients (n=50)</i>	3.6 [4.0] ± 2.7	4.2 [4.0] ± 2.8	3.7 [3.5] ± 2.8	<i>Wilcoxon</i> <i>T0-T1=0.424</i> <i>T1-T2=0.201</i> <i>T0-T2=0.809</i>
	<i>no IFN (n=36)</i>	4.0 [4.0] ± 2.9	3.4 [3.0] ± 2.5	3.7 [3.5] ± 2.8	<i>T0-T1=0.053</i> <i>T1-T2=0.376</i> <i>T0-T2=0.345</i>
	<i>IFN (n=14)</i>	2.5 [2.0] ± 2.2	6.1 [7.0] ± 2.7	3.5 [3.5] ± 2.7	<i>T0-T1=0.003</i> <i>T1-T2=0.007</i> <i>T0-T2=0.413</i>
<b>Impulsiveness</b>	<i>All patients (n=50)</i>	63.8 [62.0] ± 8.9	64.6 [64.0] ± 9.3	65.0 [66.0] ± 10.7	<i>Wilcoxon</i> <i>T0-T1=0.557</i> <i>T1-T2=0.867</i> <i>T0-T2=0.571</i>

				<i>T0-T1=0.556</i>
<i>no IFN (n=36)</i>	<i>64.3 [62.5] ± 9.3</i>	<i>63.8 [63.0] ± 9.4</i>	<i>65.1 [66.0] ± 11.7</i>	<i>T1-T2=0.616</i>
				<i>T0-T2=0.914</i>
				<i>T0-T1=0.049</i>
<i>IFN (n=14)</i>	<i>62.4 [62.0] ± 7.6</i>	<i>66.8 [66.0] ± 8.7</i>	<i>64.7 [65.5] ± 8.1</i>	<i>T1-T2=0.211</i>
				<i>T0-T2=0.448</i>

*n (%)*; <sup>a</sup> *Mean [median] ± standard deviation*; *IFN, interferon-α*; *BDI, Beck Depression Inventory*; *Hospital Anxiety and Depression Scale, depression subscale*; *HAM-D, Hamilton Depression Scale*; *HAD-A, Hospital Anxiety and Depression Scale, anxiety subscale*; *HAM-A, Hamilton Anxiety Scale*; *BFI, Brief Fatigue Inventory*; *BIS, Barrat Impulsiveness Scale*; *MINI, Mini International Neuropsychiatric Interview-Plus*; *MMES, Mini Mental Status Examination*.

<sup>1</sup>*IFN group was composed by patients who started IFN, and No-IFN group was composed by patients who did not start IFN on 18-month follow-up.*

<sup>2</sup>*(T0)=before IFN treatment; (T1)=during IFN treatment (around 12th week of IFN use); (T2)=after IFN treatment (12th week after IFN treatment completion) (T2); No-IFN group was analyzed in time points similar to those of IFN group.*